A New Cancer Treatment That Can Bind to Both Cancer Cells and T Cells Has Been Developed

The 10 hallmarks of cancer include learning to become invisible to the immune system. Immunotherapies offer an effective treatment opportunity by enabling the immune system to recognize cancer cells. In May 2018, PNAS published a study showing that a newly designed antibody drug binds both to a cancer cell and to an immune T cell, enabling destruction of the cancer cell.
Two Features of This Antibody:
- One part of the antibody binds to ROR1, a highly active receptor on cancer cells. ROR1 is a tyrosine kinase receptor on the surface of cancer cells. ROR1 is active in normal cells during embryonic development, but loses its activity in adulthood. Studies to date have detected active ROR1 receptors in breast, lung, ovarian and blood cancers. Her2 -negative breast cancer patients have high ROR1 receptor activity.
- The second part of the antibody binds to T cells and activates them. T cells are the most important white blood cells that destroy cancer cells.

What Does This Study Tell Us?
- A new antibody was designed that simultaneously binds to cancer cells and activates T cells.
- Conventional antibody treatments bind to cancer cells but cannot activate T cells. These newly designed dual-function antibodies could effectively destroy cancer cells.
- These types of antibodies may be used particularly against Her2-negative breast cancer.
These dual-function antibodies were produced using genetic engineering technologies and are called bispecific antibodies in oncology. Among bispecific antibody treatments, a type of immunotherapy, only one drug has so far received FDA approval: blinatumomab [bispecific T-cell engagers (BiTEs)], which binds to CD3 on T cells on one side and CD19 molecules on tumor cells on the other, and is used to treat acute lymphoblastic leukemia.
Sources
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
PNAS May 29, 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.